...
abbv-img

AbbVie Inc, Common Stock

ABBV

NYQ

$175.385

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$303.29B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
59.8014
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.52M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
3.82%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.61
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$145.95 L
$207.32 H
$175.385

About AbbVie Inc, Common Stock

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameABBVSectorS&P500
1-Week Return-0.17%-3.39%0.2%
1-Month Return5.47%-1.92%2.72%
3-Month Return-9.34%-10.54%7.31%
6-Month Return3.36%-4.47%10.44%
1-Year Return14.31%4.06%27.53%
3-Year Return35.4%0.94%30.88%
5-Year Return94.69%36.67%89.21%
10-Year Return163.45%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue33.27B45.80B56.20B58.05B54.32B[{"date":"2019-12-31","value":57.3,"profit":true},{"date":"2020-12-31","value":78.9,"profit":true},{"date":"2021-12-31","value":96.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.56,"profit":true}]
Cost of Revenue7.44B15.39B17.45B17.41B20.41B[{"date":"2019-12-31","value":36.44,"profit":true},{"date":"2020-12-31","value":75.37,"profit":true},{"date":"2021-12-31","value":85.46,"profit":true},{"date":"2022-12-31","value":85.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit25.83B30.42B38.75B40.64B33.90B[{"date":"2019-12-31","value":63.55,"profit":true},{"date":"2020-12-31","value":74.84,"profit":true},{"date":"2021-12-31","value":95.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.42,"profit":true}]
Gross Margin77.64%66.41%68.96%70.00%62.42%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.53,"profit":true},{"date":"2021-12-31","value":88.82,"profit":true},{"date":"2022-12-31","value":90.17,"profit":true},{"date":"2023-12-31","value":80.39,"profit":true}]
Operating Expenses12.46B17.86B19.86B21.83B21.15B[{"date":"2019-12-31","value":57.08,"profit":true},{"date":"2020-12-31","value":81.81,"profit":true},{"date":"2021-12-31","value":91.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.88,"profit":true}]
Operating Income12.98B11.36B17.92B18.12B12.76B[{"date":"2019-12-31","value":71.66,"profit":true},{"date":"2020-12-31","value":62.72,"profit":true},{"date":"2021-12-31","value":98.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.41,"profit":true}]
Total Non-Operating Income/Expense(6.07B)(10.24B)(7.32B)(6.68B)(8.19B)[{"date":"2019-12-31","value":-606600000000,"profit":false},{"date":"2020-12-31","value":-1024500000000,"profit":false},{"date":"2021-12-31","value":-731900000000,"profit":false},{"date":"2022-12-31","value":-668400000000,"profit":false},{"date":"2023-12-31","value":-819100000000,"profit":false}]
Pre-Tax Income8.43B3.40B12.99B13.48B6.25B[{"date":"2019-12-31","value":62.52,"profit":true},{"date":"2020-12-31","value":25.21,"profit":true},{"date":"2021-12-31","value":96.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.38,"profit":true}]
Income Taxes544.00M1.22B1.44B1.63B1.38B[{"date":"2019-12-31","value":33.33,"profit":true},{"date":"2020-12-31","value":75,"profit":true},{"date":"2021-12-31","value":88.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.38,"profit":true}]
Income After Taxes7.88B2.17B11.55B11.85B4.87B[{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":18.35,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}]
Income From Continuous Operations7.88B4.62B11.55B11.85B4.87B[{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income7.88B4.62B11.54B11.84B4.86B[{"date":"2019-12-31","value":66.59,"profit":true},{"date":"2020-12-31","value":39,"profit":true},{"date":"2021-12-31","value":97.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.09,"profit":true}]
EPS (Diluted)8.9410.5112.6813.8711.11[{"date":"2019-12-31","value":64.46,"profit":true},{"date":"2020-12-31","value":75.78,"profit":true},{"date":"2021-12-31","value":91.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ABBV
Cash Ratio 0.17
Current Ratio 0.65
Quick Ratio 0.54

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ABBV
ROA (LTM) 7.72%
ROE (LTM) 56.41%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ABBV
Debt Ratio Lower is generally better. Negative is bad. 0.96
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.04

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ABBV
Trailing PE 59.80
Forward PE 14.47
P/S (TTM) 5.46
P/B 50.28
Price/FCF 58
EV/R 6.61
EV/Ebitda 20.14
PEG 0.41

FAQs

What is AbbVie Inc share price today?

AbbVie Inc (ABBV) share price today is $175.385

Can Indians buy AbbVie Inc shares?

Yes, Indians can buy shares of AbbVie Inc (ABBV) on Vested. To buy AbbVie Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABBV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of AbbVie Inc be purchased?

Yes, you can purchase fractional shares of AbbVie Inc (ABBV) via the Vested app. You can start investing in AbbVie Inc (ABBV) with a minimum investment of $1.

How to invest in AbbVie Inc shares from India?

You can invest in shares of AbbVie Inc (ABBV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ABBV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in AbbVie Inc shares
What is AbbVie Inc 52-week high and low stock price?

The 52-week high price of AbbVie Inc (ABBV) is $207.32. The 52-week low price of AbbVie Inc (ABBV) is $145.95.

What is AbbVie Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of AbbVie Inc (ABBV) is 59.8014

What is AbbVie Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of AbbVie Inc (ABBV) is 50.28

What is AbbVie Inc dividend yield?

The dividend yield of AbbVie Inc (ABBV) is 3.82%

What is the Market Cap of AbbVie Inc?

The market capitalization of AbbVie Inc (ABBV) is $303.29B

What is AbbVie Inc’s stock symbol?

The stock symbol (or ticker) of AbbVie Inc is ABBV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top